One-Year Follow-Up Results From Athersys' Phase I Study of MultiStem in Heart Attack Patients Presented at International Stem Cell Symposium
Data Suggest MultiStem Provides Longer-Term Benefit in Heart Function in Heart Attack Patients Athersys, Inc. announced positive results from the analysis of one-year follow-up data from its Phase I clinical trial of MultiStem(R), its allogeneic adult stem cell product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. Dr. Marc Penn, M.D., Ph.D., co-principal investigator of this study and Director of Cardiovascular Cell Therapy at the Cleveland Clinic, and Director of the Skirball Laboratory for Cardiovascular Cellular Therapeutics, presented the results on June 10, 2011 at the Eighth International Symposium on Stem Cell Therapy and Cardiovascular Innovations in Madrid, Spain. The long-term follow-up, based on one year of patient data, suggests that trends observed at four months -- indicating a benefit in heart function from MultiStem treatment -- were continued through twelve months.
Dr. Penn presented new information from the one-year follow-up data collected from patients in the Phase I study, showing benefit in heart function through twelve months in patients treated with MultiStem.
© 2022 Pappas Capital, LLC. ALL RIGHTS RESERVED.